# Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients

Source: https://onco.cc/trials/nct03567889/  
OnCo record `nct03567889` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Daromun in melanoma, run by Philogen S.p.A., now recruiting.

## Summary

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients is a phase 3 interventional study registered as NCT03567889 by Philogen S.p.A., with 186 participants planned, started 2018-09-20 and due to reach its primary completion in 2027-12. Interventions recorded: Daromun, Surgery and Adjuvant therapy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03567889
- Phase: 3
- Setting: An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C/D Melanoma Patients
- Sponsor: Philogen S.p.A.
- Enrolled: 186

## Sources

- ClinicalTrials.gov NCT03567889: https://clinicaltrials.gov/study/NCT03567889

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- companies: [Philogen S.p.A.](https://onco.cc/companies/philogen-s-p-a/)

---
JSON: https://onco.cc/api/v1/entities/nct03567889.json